Mark G Lebwohl (Mark Lebwohl, M Lebwohl, M G Lebwohl)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 24

Top Topics

Atopic Dermatitis

Top Venues

Dermatology and therapy

Journal of the European Academy of Dermatology and Venereology : JEADV

Archives of dermatological research

This page only lists publications with an associated author ORCID identifier.

Publications

Mark G Lebwohl, Richard Bruce Warren, Howard Sofen, Shinichi Imafuku, Carle F Paul, Jacek Cezary Szepietowski, Lynda Spelman, Thierry Passeron, Eleni Vritzali, Andrew Napoli, Renata M Kisa, Alex Buck, Subhashis Banerjee, Diamant Thaҫi, Andrew Blauvelt
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. The British journal of dermatology 190 (5) (2024)
Mark G Lebwohl, April W Armstrong, Andrew F Alexis, Edward L Lain, Abby A Jacobson
Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses. Dermatology and therapy (2024)
Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, George M Martin, Nicole N Rawnsley, Earl L Goehring, Abby A Jacobson
Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and therapy 14 (5) (2024)
Phillip J Mease, Andrew Blauvelt, Adam P Sima, Silky W Beaty, Robert Low, Braulio Gomez, Marie Gurrola, Mark G Lebwohl
Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry. Dermatology and therapy (2024)
Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, George M Martin, Nicole N Rawnsley, Earl L Goehring, Abby A Jacobson
Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and therapy (2024)
Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, George M Martin, Nicole N Rawnsley, Earl L Goehring, Abby A Jacobson
Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and therapy 14 (5) (2024)
Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, George M Martin, Nicole N Rawnsley, Earl L Goehring, Abby A Jacobson
Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and therapy 14 (5) (2024)
Stefan Siebert, Emma Guttman-Yassky, Jeffrey Pawlikowski, Eric G Ghorayeb, Takayuki Ota, Mark G Lebwohl
Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies. Archives of dermatological research 316 (8) (2024)
Paolo Gisondi, Alice B Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M López Pinto, Nicola Tilt, Mark G Lebwohl
Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and therapy (2023)
Paolo Gisondi, Alice B Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M López Pinto, Nicola Tilt, Mark G Lebwohl
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and therapy 13 (1) (2022)
Paolo Gisondi, Alice B Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M López Pinto, Nicola Tilt, Mark G Lebwohl
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and therapy 13 (1) (2022)
Paolo Gisondi, Alice B Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M López Pinto, Nicola Tilt, Mark G Lebwohl
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and therapy (2022)
Paolo Gisondi, Alice B Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M López Pinto, Nicola Tilt, Mark G Lebwohl
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and therapy 13 (1) (2022)
Paolo Gisondi, Alice B Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M López Pinto, Nicola Tilt, Mark G Lebwohl
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and therapy 13 (1) (2022)
Paolo Gisondi, Alice B Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M López Pinto, Nicola Tilt, Mark G Lebwohl
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and therapy 13 (1) (2022)
Yael Renert-Yuval, Ana B Pavel, Ester Del Duca, Paola Facheris, Angel D Pagan, Swaroop Bose, Pedro J Gómez-Arias, Michael Angelov, Jennifer Bares, Margo Chima, Yeriel D Estrada, Sandra Garcet, Mark G Lebwohl, James G Krueger, Emma Guttman-Yassky
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. Allergy (2022)
Paolo Gisondi, Alice B Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M López Pinto, Nicola Tilt, Mark G Lebwohl
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and therapy 13 (1) (2022)
Paolo Gisondi, Alice B Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M López Pinto, Nicola Tilt, Mark G Lebwohl
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and therapy 13 (1) (2022)
Mark G Lebwohl, Emil A Tanghetti, Linda F Stein Gold, James Q Del Rosso, Nelly K Gilyadov, Abby Jacobson
Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits. Dermatology and therapy 11 (4) (2021)
Mark G Lebwohl, R B Warren
Editorial: fixed-dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV (2021)
Mark G Lebwohl, Linda F Stein Gold, Kim A Papp, G Han, D M Pariser, T Lin, S Harris, A Jacobson
Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (5) (2021)
Mark G Lebwohl, D Thaçi, R B Warren
Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV (2021)
Emma Guttman-Yassky, Yael Renert-Yuval, Jennifer Bares, Margot Chima, Jason E Hawkes, Patricia Gilleaudeau, Mary Sullivan-Whalen, Giselle K Singer, Sandra Garcet, Ana B Pavel, Mark G Lebwohl, James G Krueger
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients. Allergy (2021)
Richard Bruce Warren, Mark G Lebwohl, Howard Sofen, Vincent Piguet, Matthias Augustin, F Brock, null C Arendt, F Fierens, Andrew Blauvelt
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (12) (2021)